Cystic Fibrosis-related Diabetes Clinical Trial
Official title:
Comparison of Meal-Time Dosing of Rapid Acting Insulin Using Carbohydrate Counting vs. Fixed Doses Utilizing Continuous Glucose Monitoring In Patients With Cystic Fibrosis Related Diabetes
The aim of this study is to assess the utility of CGMs to determine the optimal method to dose meal-time insulin. The investigators will examine glucose excursions in patients with CF who will dose meal-time rapid-acting insulin by carbohydrate counting versus fixed-dose rapid-acting insulin. The carbohydrate ratio and fixed doses will be determined by existing doses, total daily insulin doses, body weight, and insulin sensitivity along with predisposition to hypoglycemia. Bolus insulin dosing is an important part of CFRD management due to the high nutritional demands of these patients. If dosed incorrectly, this could lead to marked hyperglycemia and could worsen nutritional status due to urinary glucose losses. In this project, the investigators will perform a within-subjects' comparison of the 2 standard methods of meal-time rapid-acting insulin dosing.
Background and Introduction Cystic fibrosis-related diabetes (CFRD) is the most common extra-pulmonary comorbidity in patients with cystic fibrosis (CF). CFRD is also associated with an accelerated decline in pulmonary function, increased pulmonary exacerbations, and increased mortality. Continuous glucose monitoring (CGM) involves the use of a small disposable sensor sited in the subcutaneous interstitial fluid that makes frequent glucose measurements. There is data suggesting that the Medtronic iPro continuous glucose monitors (CGM) can predict hemoglobin a1c levels in patients with CFRD. The aim of this study is to assess the utility of CGMs to determine the optimal method to dose meal-time insulin. The investigators will examine glucose excursions in patients with CF who will dose meal-time rapid-acting insulin by carbohydrate counting versus fixed-dose rapid-acting insulin. The carbohydrate ratio and fixed doses will be determined by existing doses, total daily insulin doses, body weight, and insulin sensitivity along with predisposition to hypoglycemia. Bolus insulin dosing is an important part of CFRD management due to the high nutritional demands of these patients. If dosed incorrectly, this could lead to marked hyperglycemia and could worsen nutritional status due to urinary glucose losses. In this project, the investigators will perform a within-subjects' comparison of the 2 standard methods of meal-time rapid-acting insulin dosing. Hypothesis: 1. Postprandial interstitial fluid glucose levels in participants who utilize carbohydrate counting to dose mealtime rapid-acting insulin will have improved control as defined as the area under the curve and time in target compared to participants who used fixed-dose mealtime insulin 2. Participants who utilize carbohydrate counting will have fewer hypoglycemia events compared to participants who use fixed-dose meal-time insulin Specific Aims: 1. To compare within-subject glucose excursions defined as the percentage of time in target glucose level, percentage of glucose in target, and peak postprandial glucose with fixed insulin dosing versus carbohydrate count based insulin dosing. 2. To compare the frequency and duration of hypoglycemia (defined as the daily, weekly, and average duration of the event) between insulin delivery methods described above. 3. To test the use of 'rule of 500' for carb counting estimation in patients with CFRD 4. To compare the effect of two methods of rapid-acting insulin delivery on fasting glycemia ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02723968 -
Cystic Fibrosis Related Diabetes Screening.
|
N/A | |
| Completed |
NCT04503408 -
A Comparison of Clinical Parameters in With and Without Abnormal Glucose Tolerance.
|
||
| Recruiting |
NCT05723445 -
The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes
|
N/A | |
| Completed |
NCT04519853 -
A Pilot Study of a Low Glycemic Load Diet in Adults With Cystic Fibrosis
|
N/A | |
| Terminated |
NCT03234387 -
A CFit Study - Baseline
|
||
| Completed |
NCT03227094 -
Simplification of CF-related Diabetes Screening at Home
|
N/A | |
| Completed |
NCT03961516 -
Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis
|
||
| Terminated |
NCT03237767 -
A CFit Study - Acute Exercise
|
N/A | |
| Withdrawn |
NCT05229640 -
Relationship Between the Development of Impaired Glucose Tolerance, the Phenotype of CFLD, and the Risk of Liver Fibrosis
|
N/A | |
| Recruiting |
NCT05766774 -
FEED-Cystic Fibrosis (FEED-CF)
|
N/A | |
| Terminated |
NCT03939065 -
Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management
|
N/A | |
| Completed |
NCT02810691 -
The Effect of Soluble Fiber to Reduce Post-prandial Glycemic Excursion in Adults With Cystic Fibrosis
|
N/A | |
| Recruiting |
NCT05568134 -
Alternate Measures of Glucose During OGTT Testing for CFRD
|
||
| Recruiting |
NCT05463289 -
ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2
|
N/A | |
| Not yet recruiting |
NCT04379726 -
β-cell Function and Insulin Sensitivity in Patients With Cystic Fibrosis
|
||
| Completed |
NCT03650712 -
EnVision CF Multicenter Study of Glucose Tolerance in Cystic Fibrosis
|
N/A | |
| Active, not recruiting |
NCT06084468 -
Cardiac Structure and Function in Patients With Cystic Fibrosis
|
||
| Recruiting |
NCT04530383 -
Effects of Metformin on Airway Ion Channel Dysfunction in Cystic Fibrosis-related Diabetes
|
Phase 2 | |
| Recruiting |
NCT06149793 -
SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05377502 -
Performance and Patient Acceptance of a Commercially Available Beverage as Compared to an Oral Glucose Solution for Oral Glucose Tolerance Tests in Cystic Fibrosis (CF) Patients Who Are Screened for CF-related Diabetes.
|